Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma

Atsuhiro Kumabe, Sadatomo Zenda, Atsushi Motegi, Masakatsu Onozawa, Naoki Nakamura, Takashi Kojima, Hiroyuki Daiko, Naoyuki Shigematsu, Tetsuo Akimoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aim: We assessed the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervical esophagus. Patients and Methods: We retrospectively analyzed 37 patients treated with definitive CCRT. The patients received radiotherapy at a fraction dose of 2 Gy (total; 60 or 70 Gy) and concurrent chemotherapy. Adjuvant chemotherapy consisted of 1 to 2 cycles of 5-fluorouracil plus cisplatin or nedaplatin. Results: The median follow-up was 119.0 months, the 10-year overall survival, progression-free survival and laryngectomy-free survival rates were 35.6, 19.9 and 30.2% respectively. In the univariate analysis, T stage (T4 vs. T1-3) was the only prognostic factor for PFS. The most common acute toxicity was leukocytopenia (Grade 3; 27%). As for late toxicities, 4 patients (11%) developed Grade 2 or 3 esophageal strictures. Conclusion: The results of this study demonstrated that CCRT yielded satisfactory clinical outcomes with acceptable toxicities.

Original languageEnglish
Pages (from-to)5039-5044
Number of pages6
JournalAnticancer Research
Volume37
Issue number9
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Chemoradiotherapy
Esophageal Stenosis
Laryngectomy
Leukopenia
Adjuvant Chemotherapy
Fluorouracil
Cisplatin
Esophagus
Disease-Free Survival
Squamous Cell Carcinoma
Radiotherapy
Survival Rate
Esophageal Squamous Cell Carcinoma
Drug Therapy
Survival

Keywords

  • Cervical esophageal carcinoma
  • Chemoradiotherapy
  • Prognostic factor
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma. / Kumabe, Atsuhiro; Zenda, Sadatomo; Motegi, Atsushi; Onozawa, Masakatsu; Nakamura, Naoki; Kojima, Takashi; Daiko, Hiroyuki; Shigematsu, Naoyuki; Akimoto, Tetsuo.

In: Anticancer Research, Vol. 37, No. 9, 01.09.2017, p. 5039-5044.

Research output: Contribution to journalArticle

Kumabe, Atsuhiro ; Zenda, Sadatomo ; Motegi, Atsushi ; Onozawa, Masakatsu ; Nakamura, Naoki ; Kojima, Takashi ; Daiko, Hiroyuki ; Shigematsu, Naoyuki ; Akimoto, Tetsuo. / Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma. In: Anticancer Research. 2017 ; Vol. 37, No. 9. pp. 5039-5044.
@article{f930e1e819c84c56be8711a81cdb058e,
title = "Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma",
abstract = "Background/Aim: We assessed the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervical esophagus. Patients and Methods: We retrospectively analyzed 37 patients treated with definitive CCRT. The patients received radiotherapy at a fraction dose of 2 Gy (total; 60 or 70 Gy) and concurrent chemotherapy. Adjuvant chemotherapy consisted of 1 to 2 cycles of 5-fluorouracil plus cisplatin or nedaplatin. Results: The median follow-up was 119.0 months, the 10-year overall survival, progression-free survival and laryngectomy-free survival rates were 35.6, 19.9 and 30.2{\%} respectively. In the univariate analysis, T stage (T4 vs. T1-3) was the only prognostic factor for PFS. The most common acute toxicity was leukocytopenia (Grade 3; 27{\%}). As for late toxicities, 4 patients (11{\%}) developed Grade 2 or 3 esophageal strictures. Conclusion: The results of this study demonstrated that CCRT yielded satisfactory clinical outcomes with acceptable toxicities.",
keywords = "Cervical esophageal carcinoma, Chemoradiotherapy, Prognostic factor, Squamous cell carcinoma",
author = "Atsuhiro Kumabe and Sadatomo Zenda and Atsushi Motegi and Masakatsu Onozawa and Naoki Nakamura and Takashi Kojima and Hiroyuki Daiko and Naoyuki Shigematsu and Tetsuo Akimoto",
year = "2017",
month = "9",
day = "1",
doi = "10.21873/anticanres.11919",
language = "English",
volume = "37",
pages = "5039--5044",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma

AU - Kumabe, Atsuhiro

AU - Zenda, Sadatomo

AU - Motegi, Atsushi

AU - Onozawa, Masakatsu

AU - Nakamura, Naoki

AU - Kojima, Takashi

AU - Daiko, Hiroyuki

AU - Shigematsu, Naoyuki

AU - Akimoto, Tetsuo

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background/Aim: We assessed the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervical esophagus. Patients and Methods: We retrospectively analyzed 37 patients treated with definitive CCRT. The patients received radiotherapy at a fraction dose of 2 Gy (total; 60 or 70 Gy) and concurrent chemotherapy. Adjuvant chemotherapy consisted of 1 to 2 cycles of 5-fluorouracil plus cisplatin or nedaplatin. Results: The median follow-up was 119.0 months, the 10-year overall survival, progression-free survival and laryngectomy-free survival rates were 35.6, 19.9 and 30.2% respectively. In the univariate analysis, T stage (T4 vs. T1-3) was the only prognostic factor for PFS. The most common acute toxicity was leukocytopenia (Grade 3; 27%). As for late toxicities, 4 patients (11%) developed Grade 2 or 3 esophageal strictures. Conclusion: The results of this study demonstrated that CCRT yielded satisfactory clinical outcomes with acceptable toxicities.

AB - Background/Aim: We assessed the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervical esophagus. Patients and Methods: We retrospectively analyzed 37 patients treated with definitive CCRT. The patients received radiotherapy at a fraction dose of 2 Gy (total; 60 or 70 Gy) and concurrent chemotherapy. Adjuvant chemotherapy consisted of 1 to 2 cycles of 5-fluorouracil plus cisplatin or nedaplatin. Results: The median follow-up was 119.0 months, the 10-year overall survival, progression-free survival and laryngectomy-free survival rates were 35.6, 19.9 and 30.2% respectively. In the univariate analysis, T stage (T4 vs. T1-3) was the only prognostic factor for PFS. The most common acute toxicity was leukocytopenia (Grade 3; 27%). As for late toxicities, 4 patients (11%) developed Grade 2 or 3 esophageal strictures. Conclusion: The results of this study demonstrated that CCRT yielded satisfactory clinical outcomes with acceptable toxicities.

KW - Cervical esophageal carcinoma

KW - Chemoradiotherapy

KW - Prognostic factor

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85029439113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029439113&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11919

DO - 10.21873/anticanres.11919

M3 - Article

C2 - 28870931

AN - SCOPUS:85029439113

VL - 37

SP - 5039

EP - 5044

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -